European Union -
English -
EMA (European Medicines Agency)
modigraf
astellas pharma europe b.v. - tacrolimus - graft rejection - immunosuppressants - prophylaxis of transplant rejection in adult and paediatric, kidney, liver or heart allograft recipients.treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adult and paediatric patients.
Israel -
English -
Ministry of Health
prograf 1 mg
astellas pharma international b.v., israel - tacrolimus - capsules - tacrolimus 1 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients.treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.
Israel -
English -
Ministry of Health
prograf 1 mg
astellas pharma international b.v., israel - tacrolimus - capsules - tacrolimus 1 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients.treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.
Israel -
English -
Ministry of Health
prograf 5 mg
astellas pharma international b.v., israel - tacrolimus - capsules - tacrolimus 5 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients. treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.
Israel -
English -
Ministry of Health
prograf 5 mg
astellas pharma international b.v., israel - tacrolimus - capsules - tacrolimus 5 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients. treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.
Israel -
English -
Ministry of Health
prograf 0.5 mg
astellas pharma international b.v., israel - tacrolimus - capsules - tacrolimus 0.5 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients. treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.
Israel -
English -
Ministry of Health
prograf 0.5 mg
astellas pharma international b.v., israel - tacrolimus - capsules - tacrolimus 0.5 mg - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients. treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.
Australia -
English -
Department of Health (Therapeutic Goods Administration)
prograf and prograf xl
janssen-cilag pty ltd - tacrolimus -
Israel -
English -
Ministry of Health
prograf ampoules
astellas pharma international b.v., israel - tacrolimus - concentrate for solution for infusion - tacrolimus 5 mg/ml - tacrolimus - tacrolimus - prophylaxis of transplant rejection in liver kidney or heart allograft recipients.treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products.
Australia -
English -
Department of Health (Therapeutic Goods Administration)
gastrografin oral liquid bottle
bayer australia ltd - amidotrizoate meglumine, quantity: 660 mg/ml; sodium amidotrizoate, quantity: 100 mg/ml - oral liquid, solution - excipient ingredients: disodium edetate; anise oil; polysorbate 80; saccharin; purified water - gastrografin is a contrast medium for examination of the gastrointestinal tract. it can be administered orally and as enema and is primarily indicated in cases in which the use barium sulfate is unsatisfactory, undesirable or contraindicated. among these are: - suspected partial or complete stenosis - acute haemorrhage - threatening perforation (peptic ulcer, diverticulum) - other acute conditions which are likely to require surgery - after resection of the stomach or the intestine (danger of perforation or leak) - megacolon - visualisation of a foreign body or tumour before endoscopy - visualisation of gastrointestinal fistula. in addition to these conditions gastrografin can generally be used for the same purposes as barium sulfate with the exception of the visualisation of mucosal diseases. due to the insufficient coating properties of gastrografin, barium sulfate should be used for single or double contrast techniques. in combination with barium sulfate, gastrografin has considerably improved routine inve